What is Apollomics?
Apollomics is a biotechnology company dedicated to the discovery and development of innovative oncology therapies. Its focus lies in creating combination treatment strategies that target specific molecular pathways and immune-related mechanisms. The company aims to enhance patient outcomes for those battling difficult-to-treat cancers by advancing drug candidates through rigorous research and development processes. This strategic approach positions Apollomics at the forefront of precision medicine in oncology.
How much funding has Apollomics raised?
Apollomics has raised a total of $240.9M across 5 funding rounds:
Angel/Seed
$5M
Series A
$9.8M
Series B
$100M
Series C
$124.2M
Debt
$2M
Angel/Seed (2016): $5M, investors not publicly disclosed
Series A (2016): $9.8M led by OrbiMed Asia
Series B (2019): $100M, investors not publicly disclosed
Series C (2020): $124.2M featuring Ping An Capital
Debt (2026): $2M, investors not publicly disclosed
Key Investors in Apollomics
OrbiMed Asia
OrbiMed Asia is a prominent investment firm with a specialized focus on the healthcare and life sciences sectors. The firm actively supports companies across various stages of development, from early-stage research to commercialization, leveraging its deep industry expertise to drive innovation and growth in biopharmaceuticals and medical technologies.
What's next for Apollomics?
With the recent influx of major strategic investment and a substantial overall funding base of $241M, Apollomics is poised for accelerated growth and the expansion of its therapeutic pipeline. The company's focus on combination therapies for oncology suggests a strategic direction towards addressing complex cancer biology. Future developments will likely involve advancing its drug candidates through clinical trials, potentially forging new partnerships, and further solidifying its market position in the competitive biotechnology landscape. The enterprise-level backing indicates confidence in Apollomics' long-term vision and its potential to deliver impactful cancer treatments.
See full Apollomics company page
